82 related articles for article (PubMed ID: 8982041)
21. Rate of iron transfer through the horse spleen ferritin shell determined by the rate of formation of Prussian Blue and Fe-desferrioxamine within the ferritin cavity.
Zhang B; Watt RK; Gálvez N; Domínguez-Vera JM; Watt GD
Biophys Chem; 2006 Mar; 120(2):96-105. PubMed ID: 16314026
[TBL] [Abstract][Full Text] [Related]
22. 2-Hydroxypyridine-N-oxides: effective new chelators in iron mobilisation.
Kontoghiorghes GJ
Biochim Biophys Acta; 1987 Apr; 924(1):13-8. PubMed ID: 3828392
[TBL] [Abstract][Full Text] [Related]
23. Combined therapy with deferiprone and desferrioxamine.
Wonke B; Wright C; Hoffbrand AV
Br J Haematol; 1998 Nov; 103(2):361-4. PubMed ID: 9827905
[TBL] [Abstract][Full Text] [Related]
24. The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner.
Watts RN; Richardson DR
Eur J Biochem; 2002 Jul; 269(14):3383-92. PubMed ID: 12135476
[TBL] [Abstract][Full Text] [Related]
25. Effects of desferrioxamine in patients with iron-loading with a simple method for estimating urinary iron.
Losowsky MS
J Clin Pathol; 1966 Mar; 19(2):165-9. PubMed ID: 5909698
[TBL] [Abstract][Full Text] [Related]
26. Phenolic ethylenediamine derivatives: a study of orally effective iron chelators.
Hershko C; Grady RW; Link G
J Lab Clin Med; 1984 Mar; 103(3):337-46. PubMed ID: 6699459
[TBL] [Abstract][Full Text] [Related]
27. A novel depot preparation of desferrioxamine-B: development of formulation principles.
Lowther N; Sparks K; Nicklin J; Jin Y
Drug Dev Ind Pharm; 1999 Nov; 25(11):1157-66. PubMed ID: 10596353
[TBL] [Abstract][Full Text] [Related]
28. Evidence for low molecular weight, non-transferrin-bound iron in rat brain and cerebrospinal fluid.
Moos T; Morgan EH
J Neurosci Res; 1998 Nov; 54(4):486-94. PubMed ID: 9822159
[TBL] [Abstract][Full Text] [Related]
29. An extended-release formulation of desferrioxamine for subcutaneous administration.
Toliyat T; Jorjani M; Khorasanirad Z
Drug Deliv; 2009 Oct; 16(7):416-21. PubMed ID: 19640256
[TBL] [Abstract][Full Text] [Related]
30. Alterations of the [59Fe]ferric citrate biodistribution in hyperferremic mice after the administration of pyrophosphate and desferrioxamine.
Sawas-Dimopoulou C; Soulpi C
J Pharmacol Exp Ther; 1983 Feb; 224(2):415-8. PubMed ID: 6296362
[TBL] [Abstract][Full Text] [Related]
31. Treatment of iron overload in adults with continuous parenteral desferrioxamine.
Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
Am J Med; 1977 Dec; 63(6):958-66. PubMed ID: 605917
[TBL] [Abstract][Full Text] [Related]
32. Determination of desferrioxamine-available iron in biological tissues by high-pressure liquid chromatography.
Gower JD; Healing G; Green CJ
Anal Biochem; 1989 Jul; 180(1):126-30. PubMed ID: 2817334
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of the metabolite N-hydroxy-desferrioxamine B.
Roggo BE; Peter HH
J Antibiot (Tokyo); 1993 Feb; 46(2):294-9. PubMed ID: 8468245
[TBL] [Abstract][Full Text] [Related]
34. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
Hussain MA; Green N; Flynn DM; Hoffbrand AV
Lancet; 1977 May; 1(8019):977-9. PubMed ID: 67469
[TBL] [Abstract][Full Text] [Related]
35. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
Hoyes KP; Porter JB
Br J Haematol; 1993 Oct; 85(2):393-400. PubMed ID: 8280612
[TBL] [Abstract][Full Text] [Related]
36. Ferritin production and desferrioxamine cytotoxicity in human neuroblastoma cell lines.
Selig RA; Madafiglio J; Haber M; Norris MD; White L; Stewart BW
Anticancer Res; 1993; 13(3):721-5. PubMed ID: 8317903
[TBL] [Abstract][Full Text] [Related]
37. Iron chelation in thalassemia: mechanism of desferrioxamine action.
Hershko C; Rachmilewitz EA
Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
[TBL] [Abstract][Full Text] [Related]
38. Chelation of thallium by combining deferasirox and desferrioxamine in rats.
Saljooghi AS; Babaie M; Mendi FD; Zahmati M; Saljooghi ZS
Toxicol Ind Health; 2016 Jan; 32(1):83-8. PubMed ID: 24021432
[TBL] [Abstract][Full Text] [Related]
39. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
Lombardo T; Ferro G; Frontini V; Percolla S
Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
[TBL] [Abstract][Full Text] [Related]
40. Evidence for participation of lipid peroxidation and iron in diquat-induced hepatic necrosis in vivo.
Smith CV
Mol Pharmacol; 1987 Sep; 32(3):417-22. PubMed ID: 3670277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
